Affordable Access

deepdyve-link
Publisher Website

Prospects for COPD treatment.

Authors
  • Matera, Maria Gabriella1
  • Cazzola, Mario2
  • Page, Clive3
  • 1 Unit of Pharmacology, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. , (Italy)
  • 2 Chair of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy. Electronic address: [email protected] , (Italy)
  • 3 Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, UK.
Type
Published Article
Journal
Current opinion in pharmacology
Publication Date
Dec 14, 2020
Volume
56
Pages
74–84
Identifiers
DOI: 10.1016/j.coph.2020.11.003
PMID: 33333428
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The management of chronic obstructive pulmonary disease (COPD) is fundamentally still heavily dependent on the use of bronchodilators and corticosteroids. Therefore, there is a need for alternative, more effective and safer therapeutic approaches. In particular, since inflammation in COPD lungs is often poorly responsive to corticosteroid treatment, novel pharmacological anti-inflammatory approaches are needed to optimally treat COPD patients. There have been multiple attempts to develop drugs that inhibit recruitment and activation of inflammatory cells, such as macrophages, neutrophils and T-lymphocytes, in the lungs of patients with COPD or target inflammatory mediators that are important in the recruitment or activation of these inflammatory cells or released by such cells. This review article focuses on novel classes of anti-inflammatory drugs that have already been tested in humans as possible treatments for patients with COPD. Copyright © 2020 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times